Diskusjon Triggere Porteføljer Aksjonærlister

ArcticZymes Technologies (AZT)

Ingenting hadde vært hyggeligere enn at de lykkes!

Salg mot aksjonærene har også tidligere blitt gjort, gjør det gjerne igjen, men det er liksom ikke aksjonærene som skal overbevises for dei er allerede overbevist, ellers hadde man ikke eigd aksjer.
Det er det øvrige markedet som helhet, så kanskje mann heller burde tatt noen utvalgte institusjoner, og tilbudt en rabattert pris på ett gitt volum, woulgan salget hitil er tilnærmet null

Collaboration to investigate yeast beta-glucan growth opportunities within land animal feed

(Tromsø, 08 May 2018) Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec BetaGlucans has today signed an agreement with Ohly GmbH to investigate potential growth opportunities within the land animal feed area

Biotec BetaGlucans and its long-time partner Ohly GmbH (part of Associated British Foods plc) have today entered into an agreement to join forces towards the land animal feed area. Purpose of the agreement is to develop the use of yeast beta-glucan within this particular market segment, based on the unique knowledge and capabilities of both companies. Target is to identify and develop growth opportunities within 18 months. Both companies will work together to ensure success in this exciting market.

“Ohly is one of our longest and most valued suppliers. By joining forces, we believe there is an excellent opportunity to further expand our mutual success story” says Biotec Pharmacon’s CEO Christian Jørgensen.

“Our yeast beta glucan product is produced from primary cultivated yeast and has demonstrated superior performance, and we are convinced that this will be of value to a broad range of farm animals” says Ohly’s Global Feed Health Platform Director, Mariët van der Werf.

Yeast beta-(1,3)/(1,6)-glucan - a major constituent of yeast cell walls – is a modulator of the immune system of animals. Beta-(1,3)/(1,6)-glucan from baker’s yeast is known to be one of the most potent immune modulating beta-glucans. Numerous scientific studies have shown that when ingested orally, yeast beta-glucan can stimulate the cells of the immune system (macrophages) thereby helping to prevent and overcome infections.

For more information, please contact:

Christian Jørgensen
CEO
+47 47 79 24 57
[email protected]

1 Like

Verdt å gi biotec en sjanse til da ?
Tar noen lodd, men frykter det kommer en emisjone etterhvert her

9.35 PM CEST / 13-May-2018 / Biotec Pharmacon ASA (OSE:BIOTEC)

Results from Neuroblastoma Phase II vaccine study indicate promising adjuvant (SBG®) effect

(Tromsø 13th May 2018) The ongoing vaccine study with Soluble Beta-Glucan (SBG®) from Biotec Pharmacon (”Biotec”, OSE: BIOTEC) as an oral adjuvant shows very promising treatment effects in children with relapsed high-risk neuroblastoma. The immuno-oncology investigators in New York, interpret a promising adjuvant effect of SBG® on cancer vaccine.

“The results (outlined below) offer further hope for children with Neuroblastoma. Additionally, this vaccine/SBG® treatment regime has an excellent safety profile with no observable side-effects”, states Chief Scientific Officer, Rolf Engstad.

The investigator team for the ongoing vaccine study with anti-GD2 vaccine combined with oral administered SBG® has presented new data from 84 patients with relapsed high-risk neuroblastoma at the “Advances in Neuroblastoma Research 2018” conference in San Francisco.

The new data strongly support the initial findings presented in 2014 from the 15-patient population cohort in the phase I part of the trial, where the two-year overall survival rate was as high as 92%. In the current phase II part of the study, having treated additional 84 patients, the 2-year overall survival (OS) rate was still 90%, with a progression free survival (PFS) rate of 51%.

The long-term survival rate in this patient population, with relapsed high-risk neuroblastoma, has been less than 20% before introduction of immunotherapeutic treatment regimes. The study thus gives promise for a significant improvement in survival rate in this patient group.

When investigating the antibody response to the vaccine, a strong correlation was observed between high antibody titre to the vaccine, and prognosis for both improved progression free survival and overall survival. In this high response subgroup, the overall survival is currently 100% five years into the trial.

Furthermore, a strong increase in the antibody response was observed with the start of administering SBG® as an oral adjuvant in the combined treatment. The initial justification of using SBG® in this combination was to strengthen the effector functions after an initial immune response was established, but the new data now indicate that SBG® also contributes in inducing an improved immune response to the vaccine itself. This holds promise for the potential use of SBG® as an oral adjuvant to increase the protective effects of other vaccines.

The role of SBG® as an adjuvant to improve the initial immune response to the vaccine, will be investigated in a follow-up trial.

“The results presented by the investigators are very promising. Biotec Pharmacon will now use the results from the Phase II trial to investigate how to further develop SBG® from both a clinical and strategic point of view”, says CEO Christian Jørgensen.

For more information, please contact:

Christian Jørgensen
CEO
Tel +47 47 79 24 57
[email protected]
About Biotec BetaGlucans AS:
Biotec BetaGlucans is a wholly owned subsidiary of Biotec Pharmacon ASA. Biotec BetaGlucans develops and manufactures novel immunomodulating products for business areas including Woulgan®, a premium priced product in the advanced wound care market, animal feed, consumer health, cosmetics, medical devices and pharmaceuticals.

About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.

This information was brought to you by Cision http://news.cision.com

Results Phase II Neuroblastoma study
If you would rather not receive future communications from Biotec Pharmacon ASA, please go to https://optout.ne.cision.com/en/3fRJ3ksYRYwiRc4qC23vvFoVdch4sYYA862t7x2TzJrAinmS5UyM63uUfXC2mhtV5BdzMr6tzimjszEQ31JuA4iF.
Biotec Pharmacon ASA, Sykehusvegen 23, Tromsø, 9019 Norway

4 Likes

Da ble det litt fart igjen her, på fint volum.
Spennende om de komme en oppgang eller om slitne aksjonærer benytter muligheten for exit

Nye insidekjøp, idag har eg også kjøpt
tilbake i biotec, etter en tid på utsiden

https://www.netfonds.no/quotes/release.php?id=20180516.OBI.20180516S66

Risikoen for en emisjon er grunnen til at eg for min del har holdt meg borte, så om den kommer, så kommer den ikke som en overraskelse for min del.
Et valgte å kjøpe litt igår, så får man heller være med i en emisjon om /når den kommer

2 Likes

@Kronn du er på kjøperen?

Nah, har tatt en og annen, men eg tør ikke noe storsatsing, eg er ikke overbevist, men fikk litt troen på insidekjøpene sist

1 Like

Da kom meldingen om at biotec planlegger en emisjon, ikke uventet og helt tiltrengt.

Har du fået købt?

Nei, ingen deltagelse for min del.
Ryktes om pris lavt på femmeren

Edit : 5,25

2 Likes

Biotec Pharmacon ASA: Invitation to presentation of Q2 2018 results

Biotec Pharmacon presents its report for the second quarter 2018
onThursday, 16.August 2018. The presentation will be given by CEO Christian
Jørgensen and CFO Børge Sørvoll
The presentation starts at 08:30 a.m. and will be in English.
Venue: Hotel Continental, Stortingsgata 24/26, Oslo.
The presentation can also be followed as a live webcast from Hegnar TV on
www.biotec.no or http://webtv.hegnar.no/presentation.php?webcastId=92028757
It will be possible to post questions through the webcast console. The interim
report for the second quarter 2018 will be available on www.newsweb.no and on
the company’s homepage, www.biotec.no from 07:00 a.m. on 16. August 2018.
For further information, please contact:
CFO
Børge Sørvoll
+47 952 90187
borge.sorvoll

Ekstern link: http://www.newsweb.no/index.jsp?messageId=456697

Nyheten er levert av OBI.

http://www.netfonds.no/quotes/release.php?id=20180808.OBI.20180808S27

Biotec Pharmacon: Results for Q2 2018

(Tromsø, August 16 2018) Biotec Pharmacon ASA (“Biotec”, OSE: BIOTEC) reported
sales of NOK 10.9 million (16.4) in the second quarter of 2018, and a negative
EBITDA of NOK 4.2 million (-4.4). ArcticZymes generated sales of NOK 5.7 million
during the second quarter whereas Woulgan® generated sales of NOK 0.5 million.
“Q2 was an active but challenging quarter with low Q2 sales. There were many
exciting developments with new ArcticZymes products and the presentation of
interim results using our SBG® as an adjuvant. However, the company experienced
headwind within the enzymes segment when comparing to Q2 2017. Furthermore, our
Animal Health business was lower than same quarter last year due to fluctuations
in our customers sales to the marine farmers and the loss of the supply
agreement mentioned in the Q1 report”, says CEO Christian Jørgensen.

The largest customer in ArcticZymes has changed their internal logistical system
to a centralized solution, whereby purchasing pattern has changed. This affected
ArcticZymes business in the 1st half of 2018, but it is expected to be regained
during the second half. The salesforce in ArcticZymes has also been altered and
it took longer than anticipated to get the expanded salesforce up to speed
delivering sales.

ArcticZymes launched 3 new products during the quarter and have launched a total
of 5 new products within the last 10 months. A broader portfolio is crucial for
continuous expansion of the business and sales. The feedback and positive
reception from customers trying out new products means that ArcticZymes will
look into expanding its production capabilities.

Woulgan generated less sales than the same quarter last year, but as reported
during the 3rd. quarter presentation in 2017, Q2 2017 had a large stock order
from Germany, which has not been repeated in terms of size. Woulgan keep getting
positive feedback from the market, but due to the nature of the market, it takes
time gain traction. Woulgan continues to search for an international partner.

During the quarter, preliminary results from the ongoing study in New York using
SBG® as an adjuvant was presented at ANR2018 in San Francisco. These results
were encouraging as to the effect of SBG®. Biotec will in cooperation with the
Neuroblastoma study partners look into the potential and timelines of this
opportunity

In the second quarter, Biotec raised NOK 22 million in a private placement
directed towards new and existing shareholders. Per end of June, the employees
of Biotec Pharmacon holds 2.7% of the shares in the company making it as a group
the fourth largest shareholder.

In connection with the second quarter announcement, CEO Christian Jørgensen also
stated: “We had expected a soft start to 2018, but Q2 was below our
expectations. However, the reasons are well understood and have been addressed.
We expect organic growth of our focus high margin areas for the whole of 2018,
whereas overall growth is uncertain. The fundamentals of our business and the
customer reaction to our products gives us confidence in the future of the
company and most of the management team bought further shares during the second
quarter. We continue to manage our cash tightly and had 14% lower spend in the
first half of 2018 versus the same period last year. We will continue to manage
the cash diligently but will also invest in new initiatives as the company will
pursue the opportunities in ArcticZymes and within SBG®.”

The complete interim report for Q2 2018 is enclosed. The company is hosting a
presentation on August 16, 2018 at 08:30 CET at Hotel Continental, Stortingsgata
24/26, Oslo.

For additional information,

Christian Jørgensen, CEO, +47 47 79 24 57 [email protected]
Børge Sørvoll CFO, +47 95 29 01 87 [email protected]

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, an advanced wound care product
for stalled wounds with a proprietary medicinal ingredient. ArcticZymes
develops, produces and markets recombinant enzymes of marine origin used in
molecular DNA technologies and diagnostics, representing growth markets where
rapid technological developments are creating a strong demand for new and
improved enz

Ekstern link: http://www.newsweb.no/index.jsp?messageId=457274

Nyheten er levert av OBI.

http://www.netfonds.no/quotes/release.php?id=20180816.OBI.20180816S2

Biotec Pharmacon: Q2 2018 Presentation

Biotec Pharmacon presents on 16 August 2018 at 08:30 its interim report for the second quarter of 2018.

Speaker at the presentation will be CEO Christian Jørgensen, MD ArcticZymes Jethro Holter and CFO Børge Sørvoll. Please find the presentation attached.

The presentation is also available as a webcast with log-on at www.biotec.no. It will be possible to submit questions to the speaker from the webcast console

Ekstern link: http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=5094486&fn=release.html
Ekstern link: http://mb.cision.com/Public/1090/2593315/82e178e1092130d1.pdf

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20180816.Cision.20180815:BIT:9515:0

Pølsebod

Lien får som fortjent, nu har han også tap på egne investeringer.

Jeg håper indelig at de får gang i AZ, ellers vil det bare være for trist.

1 Like